Business
Idorsia expands QUVIVIQ’s global footprint through new partnership with Pharmalink
Idorsia and Pharmalink enter into an exclusive distribution and commercialization agreement for QUVIVIQ™ (daridorexant) in the United Arab Emirates (UAE), Kuwait, Qatar, Oman, and Bahrain Allschwil, Switzerland – March 10, 2026Idorsia Ltd (SIX: IDIA) has entered into an exclusive agreement with Pharmalink Drug Store L.L.C for the distribution and commercialization of QUVIVIQ™ (daridorexant) – its treatment for adults with insomnia – across the United Arab Emirates (UAE), Kuwait, Qatar, Oman, and
About this update from Idorsia Ltd.
[{"type":"image","alt":"Idorsia Pharmaceuticals Ltd","displaySize":"","headline":null,"caption":"Idorsia Pharmaceuticals Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/78a4ac48860a5805262d0e653fb52e9a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/atcBYtwjtI326vFfueDYtQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/78a4ac48860a5805262d0e653fb52e9a","width":300,"height":138}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Idorsia and Pharmalink enter into an exclusive distribution and commercialization agreement for QUVIVIQ™ (daridorexant) in the United Arab Emirates (UAE), Kuwait, Qatar, Oman, and Bahrain","length":187,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":187,"olType":false},{"type":"text","content":"Allschwil, Switzerland – March 10, 2026Idorsia Ltd (SIX: IDIA) has entered into an exclusive agreement with Pharmalink Drug Store L.L.C for the distribution and commercialization of QUVIVIQ™ (daridorexant) – its treatment for adults with insomnia – across the United Arab Emirates (UAE), Kuwait, Qatar, Oman, and Bahrain.","length":322,"tagName":"p"},{"type":"text","content":"Srishti Gupta, MD, Chief Executive Officer of Idorsia, commented:“We are delighted to partner with Pharmalink, a leading healthcare provider that shares our bold vision for QUVIVIQ‘s growth across the UAE and other Gulf states. I am confident that this partnership will ensure that many patients gain access to our innovative treatment for insomnia – the only medication to have shown improvement on daytime functioning and treat insomnia as a 24-hour disorder.”","length":463,"tagName":"p"},{"type":"text","content":"Abdul Rauf Jabour, MD, Chief Executive Officer of Pharmalink, commented: "We are extremely pleased to partner with Idorsia to introduce QUVIVIQ to the UAE and the wider Gulf Cooperation Council (GCC) region. Insomnia is highly prevalent in the GCC region and an innovative brand like QUVIVIQ would rightly address the patient’s needs."","length":351,"tagName":"p"},{"type":"text","content":"Under the terms of the agreement, Idorsia will receive an upfront payment and hold the Marketing Authorizations for the countries. Upon regulatory approval, Idorsia will supply to P...